FDA Warns of Increased Risk of Serious Pancreatitis with Allergan’s Viberzi
By Zachary Brennan -
Published 15 March 2017
Following the death of two patients without a gallbladder on Allergan’s irritable bowel drug Viberzi (eluxadoline), the US Food and Drug Administration (FDA) on Wednesday warned about the increased risk of serious pancreatitis in such patients.
Categories: News, US, FDA, Crisis management, Drugs, Postmarket surveillance
Tags: Viberzi, pancreatitis, Viberzi deaths, gallbladder